AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02450526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 Units
Study NCT03059810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A
Description: Investigational Contact Lens
Study NCT01228266 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous mesenchymal stem cells
Description: A randomized double-blind, crossover study comparing treatment with autologous MSC vs. suspension media on patients with active MS
Study NCT02696915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients received ultrasound guided fascial iliaca compartment blockade using normal saline 0.9%, 40 ml
Study NCT02450526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 Units
Study NCT03902002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone 50 mg capsules
Description: Capsules containing 50 mg of omaveloxolone
Study NCT02696915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Patients received ultrasound guided fascial iliaca compartment blockade using bupivacaine 0.25%, 40 ml
Study NCT02696915 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided fascia iliaca compartment block
Description: Ultrasound guided fascia iliaca compartment block
Study NCT02696915 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound guided fascia iliaca compartment block
Description: Ultrasound guided fascia iliaca compartment block
Study NCT02696915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms)
Description: Intrathecal hyperbaric bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms
Study NCT02696915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms)
Description: Intrathecal hyperbaric bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms
Study NCT01127126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bryophyllum pinnatum, Placebo in form of Lactose
Description: Comparison Bryophyllum (2100mg/d) against Placebo (2100mg/d) regarding effectivity and safety.~Bryophyllum and Placebo are both administered for 8 weeks. Bryophyllum and Placebo are both given in form of capsules, 350mg per capsule, 2-2-2/d.
Study NCT01127126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bryophyllum pinnatum, Placebo in form of Lactose
Description: Comparison Bryophyllum (2100mg/d) against Placebo (2100mg/d) regarding effectivity and safety.~Bryophyllum and Placebo are both administered for 8 weeks. Bryophyllum and Placebo are both given in form of capsules, 350mg per capsule, 2-2-2/d.
Study NCT02896907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT03005886 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: GCF sampling
Description: GCF samples were collected using commercially available periopaper . The sample site was gently air-dried and all supragingival plaque was removed. The area was carefully isolated with cotton rolls and a saliva ejector was used to prevent the samples from being contaminated by saliva. The paper strips were inserted into the pockets until slight resistance was felt and left in place for 30s.
Study NCT01373879 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP, MVA ME-TRAP
Description: AdCh63 ME-TRAP 1 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later
Study NCT01373879 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP, MVA ME-TRAP
Description: AdCh63 ME-TRAP 5 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later
Study NCT01373879 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP, MVA ME-TRAP
Description: AdCh63 ME-TRAP 1 x 10\^10vp IM followed by MVA ME-TRAP 1 x 10\^8 pfu IM 8 weeks later
Study NCT01373879 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HDCRV
Description: HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
Study NCT01373879 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP, MVA ME-TRAP
Description: AdCh63 ME-TRAP 5 x 10\^10vp IM followed by MVA ME-TRAP 1 x 10\^8 pfu IM 8 weeks later
Study NCT01286558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 mg telmisartan
Description: once daily
Study NCT01286558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg amlodipine
Description: once daily
Study NCT01286558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mg amlodipine
Description: once daily
Study NCT01286558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg telmisartan
Description: once daily
Study NCT03534193 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Molly Center Diabetes Care Guide (Paper-based)
Description: Diabetes education with Registered Nurse in addition to Paper based education modules
Study NCT03534193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Molly Center Diabetes Care Guide (Paper-based)
Description: Diabetes education with Registered Nurse in addition to Paper based education modules
Study NCT03534193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tablet based interactive diabetes education modules
Description: Molly Center Standard Diabetes Education plus access to interactive diabetes education modules through bedside tablet.
Study NCT04917081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Self-Compassion
Description: Mindful Self-Compassion has been developed by Neff and Germer as a specific kind of Mindfulness-Based Interventions to promote self-compassion. It combines the skills of mindfulness and self-compassion, providing a powerful tool for emotional resilience and enhancing the capacity for emotional wellbeing. In this study, a shortened version of the MSC program is used which is applied once a week for 75 minutes throughout the patients' stay in the rehabilitation clinic.
Study NCT04917081 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: Progressive Muscle Relaxation by Jacobson is a deep relaxation technique that helps relieve muscle tension and is based on the premise that mental calmness is a natural result of physical relaxation. In this study, Progressive Muscle Relaxation is applied once a week for 75 minutes throughout the patients' stay in the rehabilitation clinic.
Study NCT02619448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: chemotherapy
Study NCT02619448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: chemotherapy
Study NCT02619448 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 70 Gy in 20 fractions over 4 weeks
Description: accelerated hypofractionated RT
Study NCT03005886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phase I therapy
Description: comprehensive proper plaque control program, scaling, subgingival curettage and root Phase I Periodontal Therapy planning
Study NCT03005886 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phase I therapy
Description: comprehensive proper plaque control program, scaling, subgingival curettage and root Phase I Periodontal Therapy planning
Study NCT01737892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation
Description: Epinephrine Inhalation Aerosol HFA, Single dose 125 mcg, 1 inhalation
Study NCT01737892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm C-Epinephrine Inhalation Aerosol CFC
Description: Epinephrine Inhalation Aerosol - CFC, Single dose 220 mcg, 1 inhalation
Study NCT02530255 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cycloastragenol
Description: Oral telomerase activator - cycloastragenol.
Study NCT02530255 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo (for cycloastragenol)
Description: placebo comparator, placebo for cycloastragenol.
Study NCT01348893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
Study NCT01729039 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: standard balance rehabilitation
Description: All subjects perform balance and gait exercises in addition to eye exercises and receive a written home exercise program (HEP) of balance and gait exercises to improve postural stability and mobility with progressively challenging tasks. Balance exercises include maintaining stability with vision and somatosensory cues altered, dynamic weight shifts and performing ankle, hip and step strategies. Gait activities include negotiating uneven terrains and obstacles, gait with head turns, varied speed, and unpredictable starts and stops. Walking for endurance is included in the HEP. Each participant receives a customized balance and gait HEP based on identified impairments and is progressed according to ability and level of assistance at home.
Study NCT01729039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard balance rehabilitation
Description: All subjects perform balance and gait exercises in addition to eye exercises and receive a written home exercise program (HEP) of balance and gait exercises to improve postural stability and mobility with progressively challenging tasks. Balance exercises include maintaining stability with vision and somatosensory cues altered, dynamic weight shifts and performing ankle, hip and step strategies. Gait activities include negotiating uneven terrains and obstacles, gait with head turns, varied speed, and unpredictable starts and stops. Walking for endurance is included in the HEP. Each participant receives a customized balance and gait HEP based on identified impairments and is progressed according to ability and level of assistance at home.
Study NCT01729039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: gaze stability
Description: Vestibular adaptation and substitution exercises will be performed by the experimental group (GS). Adaptation exercises involve head movement while maintaining focus on a target, which may be stationary or moving. Typical progression of adaptation exercises involve increased velocity of head movement, movement of both target and head, target placed in a distracting visual pattern and maintenance of a challenging posture. During active eye-head exercise, a large eye movement to a target is made prior to the head moving to face the target, potentially facilitating use of preprogrammed eye movements.
Study NCT01729039 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The placebo exercises will consist of saccadic eye movements while the head is stationary and will be performed by the control group. These eye movements will be performed against a plain background in order to eliminate retinal slip and, therefore, eliminate the error signal for vestibular adaptation.
Study NCT02357303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simethicone
Description: 100mL of water plus 100mg Simethicone by mouth, 15 to 30 minutes before endoscopy
Study NCT02357303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcysteine
Description: 100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine by mouth, 15 to 30 minutes before endoscopy
Study NCT02357303 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mL of water
Study NCT01450345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: The patient under Group P will be serving with 150 mg of oral Pregabalin 1 to 2 hours prior to induction.
Study NCT00688714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6482
Description: 0,9-364,5 mg administrated through intravenous infusion over 3 hours
Study NCT00688714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02225535 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NP face to face management of Chronic Low Back Pain
Description: usual NP management of chronic low back disorder
Study NCT03276104 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IOL repositioning
Description: Intraocular lens repositioning by scleral suturing
Study NCT03276104 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IOL exchange
Description: Intraocular lens exchange with retropupillary iris-claw lens
Study NCT02225535 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PT face to face management of Chronic Low Back Pain
Description: Includes manual therapy, education, exercise
Study NCT02225535 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interprofessional Videoconferencing for Chronic Low Back Pain
Description: Includes manual therapy, education, exercise.
Study NCT01226108 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patch
Description: One patch per day, Duration: three weeks, Administration: behind the ear~--------------------------------------------------------------------------------
Study NCT02092714 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02347384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta PLUS Femoral Head + SL-TWIN Stem
Description: Subject will undergo total hip arthroplasty with Delta PLUS Femoral Head \& SL-TWIN Stem
Study NCT02347384 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIOLOX forte ball head + SL-PLUS Stem
Description: Subject will undergo total hip arthroplasty with BIOLOX forte ball head \& SL-PLUS Stem
Study NCT03778801 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fibromyalgia syndrome and chronic neck pain
Description: We assessed pain intensity, kinesiophobia, fatigue, depression, physical activity level and disability in patients with fibromyalgia syndrome and chronic neck pain, and healthy individuals in this cross-sectional study.
Study NCT02940704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reciproc
Description: * Canals will be instrumented using Reciproc reciprocating system set on an electric motor, with adjusted torque and speed according to the manufacturer's instructions.~* There is no need for coronal preflaring with a Gates Glidden drill or an orifice opener since the design of the Reciproc instrument allows any obstructions in the coronal third to be removed, as claimed by the manufacturer.~* Reciproc file selection: R40 (40/0.06) is to be used.
Study NCT02940704 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One Shape
Description: * Coronal preflaring will be performed using Gates Glidden drill.~* Canals will be instrumented using One Shape single-file (25/0.06) set on an electric motor with adjusted torque and speed according to the manufacturer's instructions.~* For wide canals, One Shape Apical (30/0.06, 37/0.06) will be used.
Study NCT02662530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined either by visual/clinical or by biomechanical analysis of dystonic movements for cervical dystonia therapy in neck and shoulder muscles every 12 weeks over 30 weeks. BoNT-A dose will range from 50-300 U.
Study NCT04393246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1815
Description: EDP1815 is an orally administered pharmaceutical preparation of a single strain of Prevotella histicola isolated from the duodenum of a human donor. EDP1815 is currently in phase 2 clinical development and has European and US approval to initiate a multinational psoriasis study.
Study NCT04393246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor. Dapagliflozin is licensed for use in the UK for treatment of Type II diabetes. Since this trial is evaluating Dapagliflozin in an unlicensed indication, it is being carried out under a Clinical Trial Authorisation (CTA)
Study NCT04393246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Ambrisentan is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA). Ambrisentan was approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and indicated for the treatment of pulmonary arterial hypertension.
Study NCT04393246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Regular standard of care for COVID-19 patients
Study NCT05119023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Observational Learning
Description: All participants will complete a computer-based serial response time task intended to measure observational (implicit) learning ability. In this task, participants look at a dot move from one of 4 positions on a computer screen. Unbeknownst to participants, dot movement followed a 12-movement pattern for most experimental blocks. Eye-tracking data is collected and eye fixations within regions of interest trigger trial advancement. Learning ability is evaluated as a comparison of saccadic response times during sequenced trials relative to pseudorandomized trials.
Study NCT05119023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rule-based Learning
Description: All participants will complete a computer-based rule-based learning task intended to measure rule-based (explicit) learning ability. In this task, participants look at sequences of geometric shapes on a computer screen. Through visuals and verbal instruction, they are taught 5 rules that govern sequences. After learning rules, participants are asked to judge via button press whether novel sequences adhere to rules or not.
Study NCT00481390 — intervention group
Intervention type: PROCEDURE
Intervention: Cheek cells sample
Description: Cheek cells sample
Study NCT00481390 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample
Description: Blood sample
Study NCT00661648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)
Description: artificial pancreas
Study NCT00756730 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ATV/r
Description: Switch to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
Study NCT00756730 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DRV/r
Description: We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. Switch to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
Study NCT02129049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Participate in the Enhancing Connections Telephone Program
Study NCT02129049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-based intervention
Description: Participate in the Enhancing Connections Telephone Program
Study NCT02129049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02798835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block
Description: Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal in PACU.
Study NCT02798835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block with dexamethasone
Description: Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal along with 8mg dexamethasone IV in PACU.
Study NCT02798835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal catheter
Description: Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine and a catheter placed in PACU, with a continuous infusion of 0.2% ropivacaine started.
Study NCT02798835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Used in spinal anesthetic
Study NCT02798835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: May or may not be used in spinal anesthetic
Study NCT02896907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT02896907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT02896907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV